Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series
Rodrigues, M.J., Peron, J., Frénel, J.-S., Vano, Y.-A., Wassermann, J., Debled, M., Picaud, F., Albiges, L., Vincent-Salomon, A., Cottu, P.H.
Published in Annals of oncology (01.04.2013)
Published in Annals of oncology (01.04.2013)
Get full text
Journal Article
Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
Daban, A, Gonnin, C, Phan, L, Saldmann, A, Granier, C, Lillo-Lelouet, A, Le Beller, C, Pouchot, J, Weiss, l, Tartour, E, Fabre, E, Medioni, J, Oudard, S, Vano, YA, Dragon-Durey, MA, Simonaggio, A.
Published in Oncoimmunology (31.12.2023)
Published in Oncoimmunology (31.12.2023)
Get full text
Journal Article
Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study
Barthélémy, P., Albigès, L., Escudier, B., Narciso, B., Bigot, P., Chehimi, M., Emambux, S., Calcagno, F., Mouillet, G., Eymard, J.-C., Schlürmann, F., Bailly, S., Garbay, D., Berdah, J.-F., Palmaro, M.B., Goupil, M.G., Spaeth, D., Néré, S., Quentric, C., Vano, Y.-A., Thiery-Vuillemin, A.
Published in ESMO open (01.07.2024)
Published in ESMO open (01.07.2024)
Get full text
Journal Article
Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab
Simonaggio, A., Elaidi, R., Fournier, L., Fabre, E., Ferrari, V., Borchiellini, D., Thouvenin, J., Barthelemy, P., Thibault, C., Tartour, E., Oudard, S., Vano, Y. A.
Published in Cancer Immunology, Immunotherapy (01.12.2020)
Published in Cancer Immunology, Immunotherapy (01.12.2020)
Get full text
Journal Article
Quelle stratégie thérapeutique pour les stades métastatiques ?
Simonaggio, A., Rivallin, G., Marret, S., Oudard, S., Vano, Y.-A.
Published in Oncologie (Paris, France) (01.07.2018)
Published in Oncologie (Paris, France) (01.07.2018)
Get full text
Journal Article
Elderly patients (pts) with advanced Renal Cell Carcinoma (aRCC) treated with Nivolumab (N): A subgroup analysis from the WITNESS real-world study in France
Barthélémy, P., Thiery-Vuillemin, A., Escudier, B., Eymard, J-C., Mouillet, G., Schlürmann, F., Chartier, M., Quentric, C., Vano, Y-A., Albiges, L.
Published in European urology open science (Online) (01.11.2020)
Published in European urology open science (Online) (01.11.2020)
Get full text
Journal Article
IO-Synthesise RCC: A pooled analysis of real-world outcomes for advanced renal cell carcinoma patients treated with nivolumab in France and Germany
Thiery-Vuillemin, A., Bedke, J., Albigès, L., Bigot, P., Escudier, B., von der Heyde, E., Grünwald, V., Müller-Huesmann, H., Narciso, B., Schostak, M., Schultze-Seemann, W., Vano, Y-A., Allan, V., Chartier, M., Herber, M., McDonald, L., Quentric, C., Barthélémy, P., Grimm, M-O.
Published in European urology open science (Online) (01.11.2020)
Published in European urology open science (Online) (01.11.2020)
Get full text
Journal Article
1710P Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study
Blanchet, B., Puszkiel, A.A., Jouinot, A., Bennamoun, M., Maillet, D., Borchiellini, D., Laguerre, B., Pannier, D., Gross Goupil, M., Chevreau, C.M., Barthelemy, P., Tournigand, C., Coquan, E., Gravis, G., Kotti, S., Fridman, W-H., Sautes-Fridman, C., Oudard, S., Sun, C-M., Vano, Y-A.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
1700P Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial
Vano, Y-A., Hernandez, I., Bennamoun, M., Verkarre, V., Chevreau, C.M., Gross Goupil, M., Tournigand, C., Borchiellini, D., Laguerre, B., Maillet, D., Barthelemy, P., Gravis, G., Coquan, E., Pannier, D., Houede, N., Kotti, S., Fridman, W-H., Sautes-Fridman, C., Sun, C-M., Oudard, S.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
1468P IO-synthesise RCC: Real-world outcomes of nivolumab in patients (pts) with previously treated advanced non-clear cell renal cell carcinoma (nccRCC) – A pooled analysis from France and Germany
Barthelemy, P., Bedke, J., Albiges, L., Grünwald, V., Escudier, B., Mueller-Huesmann, H., Vano, Y-A., Ivanyi, P., Bigot, P., von der Heyde, E., Narciso, B., Belz, H., Nere, S., Quentric, C., Brellier, F., Herber, M., Thiery-Vuillemin, A., Grimm, M-O.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
1461P Impact of first-line (1L) therapy on outcomes of adult patients (pts) with metastatic MiT family translocation renal cell carcinomas (TRCC) treated in the contemporary immune checkpoint therapy (ICT) era
Thouvenin, J., Alhalabi, O., Carlo, M., Carril Ajuria, L., Bakouny, Z., Martinez Chanza, N., Negrier, S., Campedel, L., Bilen, M.A., Borchiellini, D., Chahoud, J., Vano, Y-A., Lodi, M., Barthelemy, P., Viswanathan, S.R., Msaouel, P., Choueiri, T.K., Albiges, L., Tannir, N., Malouf, G.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial
Meylan, M., Sun, C-M., Elaidi, R-T., Moreira, M., Bougouin, A., Verkarre, V., Bennamoun, M., Chevreau, C.M., Borchiellini, D., Barthelemy, P., Pannier, D., Maillet, D., Gross Goupil, M., Tournigand, C., Braychenko, E., Phan, L., Oudard, S., Fridman, W-H., Sautes-Fridman, C., Vano, Y-A.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
1460P IO-Synthesise RCC: Analysis of real-world (RW) health-related quality of life (HRQoL) outcomes with nivolumab for previously treated metastatic renal cell carcinoma (mRCC) using pooled data from France and Germany
Mouillet, G., Bedke, J., Albiges, L., Barthelemy, P., Escudier, B., Gruenwald, V., Ivanyi, P., Mueller-Huesmann, H., Vano, Y-A., von der Heyde, E., Ejzykowicz, F., Brellier, F., Herber, M., Quentric, C., Bennett, B.M., Nere, S., Autengruber, A., Thiery-Vuillemin, A., Grimm, M-O.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride in renal cell carcinoma patients with bone metastases
Elaidi, R., Vano, Y.A., Aide, N., Fournier, L., Deandreis, D., Tenenbaum, F., Lebtahi, R., De Clermont-Galleran, H., Albiges, L., Escudier, B., Joly, F., Alexandre, J., Bernardini, M., Baron, S., Arfi-Rouche, J., Noel, C., Braychenko, E., O'Quigley, J., Medioni, J., Oudard, S.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
Thérapies ciblées et biomarqueurs compagnons dans les cancers de la prostate métastatiques
Auclin, E., Vano, Y.-A.
Published in Médecine nucléaire : imagerie fonctionelle et métabolique (01.02.2014)
Published in Médecine nucléaire : imagerie fonctionelle et métabolique (01.02.2014)
Get full text
Journal Article